{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T09:46:30Z","timestamp":1792143990097,"version":"4.4.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Gastrointestinal Surgery"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.gassur.2026.102618","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T15:50:55Z","timestamp":1790783455000},"page":"102618","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Association of adjuvant immunotherapy with survival outcomes among patients with locally advanced gastric cancer after neoadjuvant immunochemotherapy: a propensity score-matched cohort study"],"prefix":"10.1016","volume":"30","author":[{"given":"Weijun","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuoyu","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenqiao","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongxuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuntong","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3683-1565","authenticated-orcid":false,"given":"Yanbing","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.gassur.2026.102618_bib1","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/s41571-023-00747-0","article-title":"Global burden of gastric cancer: epidemiological trends, risk factors, screening and prevention","volume":"20","author":"Thrift","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.gassur.2026.102618_bib2","series-title":"Chinese Society of Clinical Oncology guidelines for the diagnosis and treatment of gastric cancer: : 2026 edition","author":"Chinese Society of Clinical Oncology","year":"2026"},{"issue":"26","key":"10.1016\/j.gassur.2026.102618_bib3","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.1200\/JCO.20.02914","article-title":"Prodigy: a phase III study of neoadjuvant docetaxel, oxaliplatin, and S-1 plus surgery and adjuvant S-1 versus surgery and adjuvant S-1 for resectable advanced gastric cancer","volume":"39","author":"Kang","year":"2021","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.gassur.2026.102618_bib4","article-title":"Peri\/post-operative chemotherapy of oxaliplatin combined with S-1 (SOX) versus post-operative oxaliplatin with capecitabine (XELOX) in locally advanced gastric cancer: RESOLVE Trial","volume":"35","author":"Ji","year":"2017","journal-title":"J Clin Oncol"},{"issue":"29","key":"10.1016\/j.gassur.2026.102618_bib5","doi-asserted-by":"crossref","first-page":"3152","DOI":"10.1200\/JCO-25-00486","article-title":"Pembrolizumab plus chemotherapy versus chemotherapy as perioperative therapy in locally advanced gastric and gastroesophageal junction cancer: final analysis of the randomized, phase III KEYNOTE-585 study","volume":"43","author":"Shitara","year":"2025","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.gassur.2026.102618_bib6","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.5557","article-title":"Association of adjuvant chemotherapy with overall survival among patients with locally advanced gastric cancer after neoadjuvant chemotherapy","volume":"5","author":"Lin","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.gassur.2026.102618_bib7","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1245\/s10434-024-16365-8","article-title":"Downstaging effect rather than the full intended cycles of perioperative chemotherapy determines the value of adjuvant chemotherapy in gastric cancer","volume":"32","author":"Li","year":"2024","journal-title":"Ann Surg Oncol"},{"issue":"17","key":"10.1016\/j.gassur.2026.102618_bib8","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.2217\/imt-2021-0085","article-title":"Durable response after immunotherapy discontinuation for delayed and severe immune-related adverse events: a case report","volume":"13","author":"Pesola","year":"2021","journal-title":"Immunotherapy"},{"key":"10.1016\/j.gassur.2026.102618_bib9","article-title":"Correlation of the gut microbiome and immune-related adverse events in gastrointestinal cancer patients treated with immune checkpoint inhibitors","volume":"13","author":"Zhang","year":"2023","journal-title":"Front Cell Infect Microbiol"},{"issue":"9","key":"10.1016\/j.gassur.2026.102618_bib10","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.gassur.2026.102618_bib11","first-page":"440","article-title":"Tumor microenvironment can promote cancer cell invasion and foster immune suppression","volume":"7","author":"Gao","year":"2024","journal-title":"Trans Mater Biotechnol Life Sci"},{"key":"10.1016\/j.gassur.2026.102618_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2024.101080","article-title":"Circumventing drug resistance in gastric cancer: a spatial multi-omics exploration of chemo and immuno-therapeutic response dynamics","volume":"74","author":"Che","year":"2024","journal-title":"Drug Resist Updat"},{"issue":"5","key":"10.1016\/j.gassur.2026.102618_bib13","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.annonc.2021.02.004","article-title":"Checkpoint inhibitors for gastroesophageal cancers: dissecting heterogeneity to better understand their role in first-line and adjuvant therapy","volume":"32","author":"Smyth","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.gassur.2026.102618_bib14","series-title":"Common Terminology Criteria for Adverse Events (CTCAE) [Internet]. Version 5.0","author":"US Department of Health and Human Services","year":"2017"},{"issue":"14:","key":"10.1016\/j.gassur.2026.102618_bib15","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1200\/JCO.2020.38.4_suppl.347","article-title":"Prognostic impact of immune-related adverse events with nivolumab in patients with advanced gastric cancer: a multicenter retrospective analysis","volume":"38","author":"Ohya","year":"2020","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.gassur.2026.102618_bib16","doi-asserted-by":"crossref","first-page":"5902","DOI":"10.1007\/s00464-023-10052-7","article-title":"Comparison of short- and long-term outcomes between laparoscopic and open gastrectomy for locally advanced gastric cancer following neoadjuvant chemotherapy: a propensity score matching analysis","volume":"37","author":"Zhong","year":"2023","journal-title":"Surg Endosc"},{"issue":"1","key":"10.1016\/j.gassur.2026.102618_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejso.2024.109459","article-title":"Short- and long-term outcomes following perioperative ERAS management in patients undergoing minimally invasive radical gastrectomy after neoadjuvant chemotherapy: a single-center retrospective propensity score matching study","volume":"51","author":"Liu","year":"2025","journal-title":"Eur J Surg Oncol"},{"issue":"1","key":"10.1016\/j.gassur.2026.102618_bib18","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1097\/SLA.0000000000004908","article-title":"Randomized controlled trial comparing the short-term outcomes of Enhanced Recovery after Surgery and conventional care in laparoscopic distal gastrectomy (GISSG1901)","volume":"275","author":"Tian","year":"2022","journal-title":"Ann Surg"},{"issue":"2","key":"10.1016\/j.gassur.2026.102618_bib19","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","article-title":"Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey","volume":"240","author":"Dindo","year":"2004","journal-title":"Ann Surg"},{"issue":"2","key":"10.1016\/j.gassur.2026.102618_bib20","doi-asserted-by":"crossref","first-page":"167","DOI":"10.6004\/jnccn.2022.0008","article-title":"Gastric cancer, version 2.2022, NCCN clinical practice guidelines in oncology","volume":"20","author":"Ajani","year":"2022","journal-title":"J Natl Compr Cancer Netw"},{"issue":"1","key":"10.1016\/j.gassur.2026.102618_bib21","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s12957-026-04224-7","article-title":"The association of survival with adjuvant chemotherapy in patients with ypTNM stage I gastric cancer after neoadjuvant chemotherapy","volume":"24","author":"Liu","year":"2026","journal-title":"World J Surg Oncol"},{"issue":"3","key":"10.1016\/j.gassur.2026.102618_bib22","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1245\/s10434-024-16585-y","article-title":"Effect of adjuvant chemotherapy cycles on patients with node-negative gastric cancer following neoadjuvant chemotherapy: multicenter cohort study","volume":"32","author":"Yu","year":"2025","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"10.1016\/j.gassur.2026.102618_bib23","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1186\/s12957-023-03251-y","article-title":"Optimal timing of surgery for gastric cancer after neoadjuvant chemotherapy: a systematic review and meta-analysis","volume":"21","author":"Ling","year":"2023","journal-title":"World J Surg Oncol"},{"issue":"8","key":"10.1016\/j.gassur.2026.102618_bib24","article-title":"Optimizing surgical timing following neoadjuvant therapy for gastric cancer: insights from a multicenter retrospective analysis","volume":"51","author":"Chen","year":"2025","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.gassur.2026.102618_bib25","article-title":"Predictive biomarkers in the era of immunotherapy for gastric cancer: current achievements and future perspectives","volume":"16","author":"Sun","year":"2025","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.gassur.2026.102618_bib26","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1200\/JCO.2011.39.1953","article-title":"Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial","volume":"30","author":"Lee","year":"2012","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.gassur.2026.102618_bib27","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1200\/JCO.2010.33.0597","article-title":"Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial","volume":"29","author":"Ychou","year":"2011","journal-title":"J Clin Oncol"},{"issue":"20","key":"10.1016\/j.gassur.2026.102618_bib28","doi-asserted-by":"crossref","first-page":"15321","DOI":"10.3390\/ijms242015321","article-title":"Predictive biomarkers for immunotherapy in gastric cancer: current status and emerging prospects","volume":"24","author":"Hou","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10.1016\/j.gassur.2026.102618_bib29","first-page":"451","article-title":"Immune checkpoint inhibitors: breakthroughs in cancer treatment","volume":"21","author":"Kong","year":"2024","journal-title":"Cancer Biol Med"},{"issue":"8","key":"10.1016\/j.gassur.2026.102618_bib30","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1016\/j.cell.2023.03.006","article-title":"Immune checkpoint therapy-current perspectives and future directions","volume":"186","author":"Sharma","year":"2023","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.gassur.2026.102618_bib31","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/s41392-022-01136-2","article-title":"Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response","volume":"7","author":"Wang","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.gassur.2026.102618_bib32","article-title":"Clinical significance of the tumor microenvironment on immune tolerance in gastric cancer","volume":"16","author":"He","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.gassur.2026.102618_bib33","article-title":"Tumor microenvironment-mediated immune tolerance in development and treatment of gastric cancer","volume":"13","author":"Liu","year":"2022","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.gassur.2026.102618_bib34","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s40364-022-00413-0","article-title":"Advances in molecular biomarkers research and clinical application progress for gastric cancer immunotherapy","volume":"10","author":"Cai","year":"2022","journal-title":"Biomark Res"},{"issue":"9","key":"10.1016\/j.gassur.2026.102618_bib35","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1158\/2159-8290.CD-21-0857","article-title":"Dissecting response and resistance to anti\u2013PD-1 therapy in microsatellite-unstable gastric cancer","volume":"11","author":"Fontana","year":"2021","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1016\/j.gassur.2026.102618_bib36","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s13045-022-01242-2","article-title":"Improvement of the anticancer efficacy of PD-1\/PD-L1 blockade via combination therapy and PD-L1 regulation","volume":"15","author":"Wu","year":"2022","journal-title":"J Hematol Oncol"},{"issue":"4","key":"10.1016\/j.gassur.2026.102618_bib37","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s41571-022-00600-w","article-title":"Immune-checkpoint inhibitors: long-term implications of toxicity","volume":"19","author":"Johnson","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.gassur.2026.102618_bib38","series-title":"ESMO Congress","author":"Tabernero","year":"2025"},{"issue":"29","key":"10.1016\/j.gassur.2026.102618_bib39","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1200\/JCO-25-01439","article-title":"KEYNOTE-585 fails while Matterhorn succeeds in gastric cancer: what lessons can we learn?","volume":"43","author":"Ilson","year":"2025","journal-title":"J Clin Oncol"}],"container-title":["Journal of Gastrointestinal Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1091255X26002994?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1091255X26002994?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T09:09:57Z","timestamp":1792141797000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1091255X26002994"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":39,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["S1091255X26002994"],"URL":"https:\/\/doi.org\/10.1016\/j.gassur.2026.102618","relation":{},"ISSN":["1091-255X"],"issn-type":[{"value":"1091-255X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association of adjuvant immunotherapy with survival outcomes among patients with locally advanced gastric cancer after neoadjuvant immunochemotherapy: a propensity score-matched cohort study","name":"articletitle","label":"Article Title"},{"value":"Journal of Gastrointestinal Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gassur.2026.102618","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Society for Surgery of the Alimentary Tract. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102618"}}